Actavis Expands in Women’s Health with Uteron Pharma Purchase

Abstract

Watson Pharmaceuticals, now officially known as Actavis, has acquired the Belgium-based women’s healthcare company Uteron Pharma in a deal worth up to US$305 M in order to expand its late-stage branded product pipeline. Levosert, an intrauterine device, is currently awaiting a regulatory decision in several EU countries and Diafert, an immunoassay kit for the assessment of oocyte quality during in vitro fertilisation, is expected to obtain a CE mark in the EU later in 2013. Actavis has been an active dealmaker in women’s health in recent years.